Chronic kidney disease¿mineral and bone disorder (CKD-MBD): Current perspectives

• Type: Another Publication in an International Scientific Journal
• Date: 2019

Authors

Waziri B. (Author) Other; Duarte R (Author) Other; Naicker S. (Author) Other

Journal

The Journal is awaiting validation by the Administrative Services.

Title: International Journal of Nephrology and Renovascular Disease

Vol. 43

Pages: 263-276

Publisher: Informa UK Limited

Indexing

Scopus - 71 Citations

Other information

Authenticus ID: P-010-SVZ

DOI: 10.2147/ijnrd.s191156

Abstract (EN): Despite the availability of global and regional guidelines to curtail the adverse clinical outcomes associated with chronic kidney disease¿mineral and bone disorder (CKD-MBD), most CKD patients are still affected by the consequences of abnormalities of CKD-MBD. This important clinical complication of CKD continues to be studied, in order to improve the understanding and management of CKD-MBD. Some notable discoveries include the role of fibroblast growth factor 23 (FGF23) in the pathogenesis of CKD-MBD, leading to a shift from the previous well-established classic trade-off hypothesis to the updated trade-off hypothesis. More recently, there has been a shift from the treatment of CKD-MBD based on a single level of biomarkers to serial measurements of calcium, phosphate and parathyroid hormone (PTH). Furthermore, some clinical trials have emerged after the 2009 Kidney Disease-Improving Global Outcomes (KDIGO) Guidelines, leading to the 2017 KDIGO updated recommendations. Hence, this review gives an overview of the rapidly evolving trends in CKD-MBD, linking the past and current concepts of CKD-MBD.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 13